FLUMESOL-200 WS

Indications

• Bacterial infections
• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections
• Gastrointestinal infections

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Flumequin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication, transcription, and repair. This inhibition disrupts the supercoiling of DNA, leading to cell death. Its action is primarily bactericidal, targeting actively dividing bacteria.

Pharmacodynamics

Flumequin demonstrates time-dependent antibacterial activity, with its efficacy linked to the duration of exposure above the minimum inhibitory concentration (MIC). It has a wide therapeutic window and is effective against a variety of pathogens. Resistance mechanisms may include mutations in target enzymes or efflux pump activity.

Pharmacokinetics

Flumequin is well absorbed following oral administration, with peak plasma concentrations typically achieved within a few hours. It is metabolized in the liver and excreted via urine, with a half-life that may vary based on individual patient factors. The drug's bioavailability and distribution are influenced by factors such as age, renal function, and concurrent medications.

Pregnancy

Flumequin should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether flumequin is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, protected from light.